| (PD-022) PARP-ness in metastatic colorectal cancer G Mauri, K Kanter, M Fish, N Horick, J Allen, L Blaszkowsky, J Clark, ... Ann Oncol 30, 117, 2019 | 2 | 2019 |
| 1089 Improved safety of capecitabine vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT phase III study) M Nowacki, H Kroning, A Cervantes, F Husseini, J McKendrick, J Schuller, ... EJC Supplements 5 (1), S326, 2003 | 5 | 2003 |
| 1132 POSTER Epithelial-Mesenchymal Transition in Cancer of Unknown Primary A Stovianni, A Goussia, G Pentheroudakis, V Siozopoulou, A Cervantes, ... European Journal of Cancer, S133, 2011 | | 2011 |
| 1201P The role of a mini tumour mutational burden (TMB) score generated with a customized NGS panel to predict benefit from immunotherapy P Lombardi, V Gambardella, N Tarazona, JA Carbonell-Asins, ... Annals of Oncology 31, S789, 2020 | | 2020 |
| 138 Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer M Ibarrola-Villava, MJ Llorca-Cardeñosa, N Tarazona, C Mongort, ... European Journal of Cancer 3 (51), S11, 2015 | | 2015 |
| 1471P 3D patient-derived gastric cancer organoids as a tool for functional precision medicine for gastric cancer patients M Cabeza, F Papaccio, MFG Bravo, V Gambardella, C Alfaro-Cervello, ... Annals of Oncology 31, S919, 2020 | | 2020 |
| 1480P M2 macrophages could promote an immunosuppressive phenotype in a prospective cohort of advanced gastric cancer patients M Cabeza, V Gambardella, L Alarcón, G Herrera, Z Garzón-Lloría, ... Annals of Oncology 31, S922, 2020 | | 2020 |
| 1493P An integrated analysis of gene expression profile and chromosomal aberrations highlighted the oxidative stress role in anti-HER2 drug-resistant gastric cancer models V Gambardella, F Gimeno-Valiente, M Cabeza, F Papaccio, ... Annals of Oncology 31, S927, 2020 | | 2020 |
| 14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC) M Peeters, T Price, Y Hotko, A Cervantes, M Ducreux, T André, E Chan, ... EJC Supplements 3 (7), 10, 2009 | 69 | 2009 |
| 152 EGF-induced acetylation of heterogeneous nuclear ribonucleoproteins is dependent on KRAS mutational status in colorectal cancer cells D Roda, J Castillo, M Telechea, A Gil, G Lopez, L Franco, ... European Journal of Cancer 3 (51), S15, 2015 | | 2015 |
| 1565P Clinical outcome after perioperative treatment on locally advanced and borderline pancreatic cancer: Experience of a single academic center SR Keränen, C Pizzo, M Huerta, E Muñoz, C Alfaro-Cervello, R Aliaga, ... Annals of Oncology 31, S954, 2020 | | 2020 |
| 1595P Connecting primary care with oncology through the implementation a cancer fast-track program: Reducing time from initial symptoms to diagnosis and initiation of treatment … MTM Martinez, B Ortega, S Simon, S Moragon, J Navarro, A Sanmartin, ... Annals of Oncology 31, S964, 2020 | 1 | 2020 |
| 1820P Taxane-related skin toxicity: Analysis of an in vivo and 3D in vitro model study of the impact of paclitaxel on skin M Perez-Leal, JAP Fidalgo, C Sanz, J Poveda, J Milara, P Martinez, ... Annals of Oncology 31, S1050, 2020 | | 2020 |
| 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG … A Du Bois, M Quinn, T Thigpen, J Vermorken, E Avall-Lundqvist, ... Annals of oncology 16 (SUPPL. 8), viii7-viii12, 2005 | 477 | 2005 |
| 2118 Quality of life (QoL) during second-line treatment with FOLFIRI+/-panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC) AF Sobrero, TJ Price, A Cervantes, M Ducreux, T Andre, F Lordick, ... European Journal of Cancer 3 (51), S369-S370, 2015 | | 2015 |
| 2188 Prognostic role of the LCS-6 KRAS variant in locally advanced rectal cancer: Results of the EXPERT-C trial F Sclafani, I Chau, D Cunningham, C Peckitt, A Lampis, JC Hahne, ... European Journal of Cancer 3 (51), S396, 2015 | | 2015 |
| 2393 Role of RUNX3 expression in peritumoral infiammatory infiltrate of gastric carcinoma MJL Cardeñosa, T Fleitas, S Navarro, C Mongort, S Roselló, ... European Journal of Cancer 3 (51), S468, 2015 | | 2015 |
| 26 Is a side effect of molecular targeted therapy a marker of efficacy? J Tabernero, J Rodon, R Dienstmann, I Braña, A Cervantes Ejc Supplements 7 (8), 18, 2010 | | 2010 |
| 27. Differences in adjuvant chemotherapy administration for stage II colon cancer patients–a EURECCA international comparison A Breugom, PG Boelens, E Bastiaannet, L Van Eycken, LH Iversen, ... European Journal of Surgical Oncology 40 (11), S20, 2014 | | 2014 |
| 2748 Assessment of associations between disease stage and toxicity with bevacizumab (BEV) in ICON7, a phase III trial of front-line carboplatin/paclitaxel (CP)±BEV for ovarian … AC Embleton, TJ Perren, A Cook, E Kent, J Pfisterer, JA Ledermann, ... European Journal of Cancer 3 (51), S546, 2015 | | 2015 |
Susana RosellóMedical Doctor in Hospital Clinico Universitario of Valencia, SpainDirección de correo verificada de incliva.es
